Vestal Point Capital, LP Ultragenyx Pharmaceutical Inc. Transaction History
Vestal Point Capital, LP
- $1.4 Trillion
- Q1 2025
A detailed history of Vestal Point Capital, LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 500,000 shares of RARE stock, worth $20.7 Million. This represents 1.29% of its overall portfolio holdings.
Number of Shares
500,000
Previous 1,500,000
66.67%
Holding current value
$20.7 Million
Previous $63.1 Billion
71.31%
% of portfolio
1.29%
Previous 3.74%
Shares
5 transactions
Others Institutions Holding RARE
# of Institutions
337Shares Held
89.8MCall Options Held
1.08MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10MShares$414 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$232 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$173 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$133 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$109 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.9B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...